Navigating the challenges of Meniere disease

Pullen, Richard L.

doi:10.1097/01.nurse.0000520504.06428.ce

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects of sex on medical care and behavioral therapies have not been examined following treatment of women with MD ( 22 ). MD is most prevalent between the ages of 40 and 60 years, with a peak onset at 40-50 years ( 23 , 24 ).…”

Section: Discussionmentioning

confidence: 99%

Effects of hormone therapy containing 2 mg drospirenone and 1 mg 17β‑estradiol on postmenopausal exacerbation of Meniere's disease: Preliminary study

et al. 2021

View full text Add to dashboard Cite

The present study aimed to evaluate the effects of 2 mg drospirenone (DRSP) and 1 mg 17β-estradiol (E2) hormone therapy (HT) in combination with rehabilitation therapy for postmenopausal women with Meniere's disease (MD). The combined drug hormone treatment was denoted as DRSP/E2. A total of 65 postmenopausal female patients with MD and severe distress were enrolled in the present prospective study. A total of 31 women comprised the study group (group A), undergoing HT and rehabilitation therapy, whereas 34 women who opted for rehabilitation therapy alone comprised the control group (group B). Vestibular function and distress associated with MD were assessed by stabilometry and the Dizziness Handicap Inventory (DHI) questionnaire, respectively. The data were collected at baseline and during the 3- and 6-month follow-up visits. The areas of the stabilometric ellipses exhibited a higher reduction in group A compared with group B with regard to the baseline values at both follow-up assessments (P<0.001). At baseline, both groups exhibited severe self-perceived discomfort, with similar DHI scores of 72.3±3.7 (group A) and 70.6±3.9 (group B; P=0.07). At the 3-month follow-up, both groups underwent a gradual improvement, which was significantly higher in group A (47.5±3.7) compared with in group B (64.2±3.3; P<0.001). At the 6-month follow-up, the DHI scores were improved in group A (43.4±3.4) compared with in group B (58.5±3.1; P<0.001). Therefore, DRSP/E2 HT was effective in reducing the fluid overload, which is characteristic of MD. The findings of the present study demonstrated that integrated therapy based on the administration of DRSP/E2 HT and rehabilitation may be more effective compared with rehabilitation alone for the management of postmenopausal exacerbation of MD.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of hormone therapy containing 2 mg drospirenone and 1 mg 17β‑estradiol on postmenopausal exacerbation of Meniere's disease: Preliminary study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The most striking features of MD are rotatory vertigo and hearing loss, which show great variability among patients with respect to onset, duration and severity ( 10 , 11 ). Vertigo attacks can last from several minutes to hours, and are often incapacitating due to their unpredictability and impact on quality of life ( 12 ). In initial stages of the disease, hearing loss is typically reversible after each vertigo attack, but profound and permanent hearing loss ultimately develops ( 13 ).…”

Section: Introductionmentioning

confidence: 99%

Hydropic Ear Disease: Correlation Between Audiovestibular Symptoms, Endolymphatic Hydrops and Blood-Labyrinth Barrier Impairment

et al. 2021

View full text Add to dashboard Cite

Research Objective: To investigate the correlation between clinical features and MRI-confirmed endolymphatic hydrops (EH) and blood-labyrinth barrier (BLB) impairment.Study Design: Retrospective cross-sectional study.Setting: Vertigo referral center (Haga Teaching Hospital, The Hague, the Netherlands).Methods: We retrospectively analyzed all patients that underwent 4 h-delayed Gd-enhanced 3D FLAIR MRI at our institution from February 2017 to March 2019. Perilymphatic enhancement and the degree of cochlear and vestibular hydrops were assessed. The signal intensity ratio (SIR) was calculated by region of interest analysis. Correlations between MRI findings and clinical features were evaluated.Results: Two hundred and fifteen patients with MRI-proven endolymphatic hydrops (EH) were included (179 unilateral, 36 bilateral) with a mean age of 55.9 yrs and median disease duration of 4.3 yrs. Hydrops grade is significantly correlated with disease duration (P < 0.001), the severity of low- and high-frequency hearing loss (both P < 0.001), and the incidence of drop attacks (P = 0.001). Visually increased perilymphatic enhancement was present in 157 (87.7%) subjects with unilateral EH. SIR increases in correlation with hydrops grade (P < 0.001), but is not significantly correlated with the low or high Fletcher index (P = 0.344 and P = 0.178 respectively). No significant differences were found between the degree of EH or BLB impairment and vertigo, tinnitus or aural fullness.Conclusion: The degree of EH positively correlates with disease duration, hearing loss and the incidence of drop attacks. The BLB is impaired in association with EH grade, but without clear contribution to the severity of audiovestibular symptoms.

show abstract

Effects of combined oral contraception containing drospirenone on premenstrual exacerbation of Meniere’s disease: Preliminary study

Caruso

Mauro

Maiolino

et al. 2018

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

Navigating the challenges of Meniere disease

Cited by 4 publications

References 7 publications

Effects of hormone therapy containing 2 mg drospirenone and 1 mg 17β‑estradiol on postmenopausal exacerbation of Meniere's disease: Preliminary study

Effects of hormone therapy containing 2 mg drospirenone and 1 mg 17β‑estradiol on postmenopausal exacerbation of Meniere's disease: Preliminary study

Hydropic Ear Disease: Correlation Between Audiovestibular Symptoms, Endolymphatic Hydrops and Blood-Labyrinth Barrier Impairment

Effects of combined oral contraception containing drospirenone on premenstrual exacerbation of Meniere’s disease: Preliminary study

Contact Info

Product

Resources

About